Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor-neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear. METHODS: We randomly assigned 4822 patients with New York Heart Association (NYHA) class II to IV heart failure, ejection fraction of 45% or higher, elevated level of natriuretic peptides, and structural heart disease to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or valsartan (target dose, 160 mg twice daily). The primary outcome was a composite of total hospitalizations for heart failure and death from cardiovascular causes. Primary outcome components, secondary outcomes (including NYHA class change, worsening renal function, and change in Kansas City Cardiomyopathy Questionnaire [KCCQ] clinical summary score [scale, 0 to 100, with higher scores indicating fewer symptoms and physical limitations]), and safety were also assessed. RESULTS: There were 894 primary events in 526 patients in the sacubitril-valsartan group and 1009 primary events in 557 patients in the valsartan group (rate ratio, 0.87; 95% confidence interval [CI], 0.75 to 1.01; P = 0.06). The incidence of death from cardiovascular causes was 8.5% in the sacubitril-valsartan group and 8.9% in the valsartan group (hazard ratio, 0.95; 95% CI, 0.79 to 1.16); there were 690 and 797 total hospitalizations for heart failure, respectively (rate ratio, 0.85; 95% CI, 0.72 to 1.00). NYHA class improved in 15.0% of the patients in the sacubitril-valsartan group and in 12.6% of those in the valsartan group (odds ratio, 1.45; 95% CI, 1.13 to 1.86); renal function worsened in 1.4% and 2.7%, respectively (hazard ratio, 0.50; 95% CI, 0.33 to 0.77). The mean change in the KCCQ clinical summary score at 8 months was 1.0 point (95% CI, 0.0 to 2.1) higher in the sacubitril-valsartan group. Patients in the sacubitril-valsartan group had a higher incidence of hypotension and angioedema and a lower incidence of hyperkalemia. Among 12 prespecified subgroups, there was suggestion of heterogeneity with possible benefit with sacubitril-valsartan in patients with lower ejection fraction and in women. CONCLUSIONS: Sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes among patients with heart failure and an ejection fraction of 45% or higher. (Funded by Novartis; PARAGON-HF ClinicalTrials.gov number, NCT01920711.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the PARAGON-HF trial (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction), neprilysin inhibition reduced the risk of cardiovascular death and total hospitalizations by 13%, improved KCCQ by 1.0 points, and had no overall effect on the EuroQol Visual Analog Scale.3,9”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Self-citationYusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationIrbesartan in patients with heart failure and preserved ejection fraction
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805450 · Cited by 1,960
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Zile, M. R., Baicu, C. F., & Gaasch, W. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032566 · Cited by 1,563
Self-citationThe perindopril in elderly people with chronic heart failure (PEP-CHF) study
Cleland, J. G. F. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl250 · Cited by 1,508
Self-citationSolomon, S. D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E., Shi, V., Bransford, T., Takeuchi, M., Gong, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61227-6 · Cited by 1,173
Self-citationPhenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction
Shah, S. J., Katz, D. H., Selvaraj, S., Burke, M. A., Yancy, C. W., Gheorghiade, M., Bonow, R. O., Huang, C.-C., & Deo, R. C. (2015) · Circulation · doi:10.1161/circulationaha.114.010637 · Cited by 1,157
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Research works printed but not linked: 1
- Cowling BJ, Hutton JL, Shaw JEH. Joint modeling of event counts and sur- vival times. Appl Stat 2006; 55: 31-9.
Cited by
Items 101–200 of 1,000
Vaduganathan, M., Claggett, B. L., Desai, A. S., Anker, S. D., Perrone, S. V., Janssens, S. P., Miličić, D., Arango, J. L., Packer, M., Shi, V. C., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.003 · Cited by 154
“The design (11) and principal results (10) of PARAGON-HF have been previously reported.”
BackgroundSelf-citationKozhuharov, N., Goudev, A., Flores, D., Maeder, M. T., Walter, J., Shrestha, S., Gualandro, D. M., de Oliveira Junior, M. T., Sabti, Z., Müller, B., et al. (2019) · JAMA · doi:10.1001/jama.2019.18598 · Cited by 136
Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4
Díez, J., González, A., & Kovacic, J. C. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.019 · Cited by 157
Coronary blood flow in heart failure: cause, consequence and bystander
Heusch, G. (2022) · Basic Research in Cardiology · doi:10.1007/s00395-022-00909-8 · Cited by 156
Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.11.027 · Cited by 178
Self-citationAnker, S. D., Butler, J., Filippatos, G., Shahzeb Khan, M., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner-La Rocca, H. P., Choi, D.-J., Chopra, V., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2064 · Cited by 133
Self-citationcGMP: a unique 2nd messenger molecule – recent developments in cGMP research and development
Friebe, A., Sandner, P., & Schmidtko, A. (2019) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-019-01779-z · Cited by 154
Yurista, S. R., Matsuura, T. R., Silljé, H. H. W., Nijholt, K. T., McDaid, K. S., Shewale, S. V., Leone, T. C., Newman, J. C., Verdin, E. M., van Veldhuisen, D. J., et al. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007684 · Cited by 146
Sachdev, V., Sharma, K., Keteyian, S. J., Alcain, C. F., Desvigne-Nickens, P. M., Fleg, J. L., Florea, V. G., Franklin, B. A., Guglin, M. E., Halle, M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001122 · Cited by 161
Kapłon‐Cieślicka, A., Benson, L., Chioncel, O. D., Crespo-Leiro, M. G., Coats, A. J. S., Anker, S. D., Filippatos, G. S., Ruschitzka, F. T., Hage, C., Dróżdż, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2408 · Cited by 159
Self-citationTomasoni, D., Inciardi, R. M., Lombardi, C. M., Tedino, C., Agostoni, P., Ameri, P., Barbieri, L., Bellasi, A., Camporotondo, R., Canale, C., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2052 · Cited by 128
Self-citationBackhaus, S. J., Lange, T., George, E. F., Hellenkamp, K., Gertz, R. J., Billing, M., Wachter, R., Steinmetz, M., Kutty, S., Raaz, U., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051542 · Cited by 141
Davies, D. R., Redfield, M. M., Scott, C. G., Minamisawa, M., Grogan, M. A., Dispenzieri, A. A., Chareonthaitawee, P., Shah, A. M., Shah, S. J., Wehbe, R. M., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.1781 · Cited by 141
Self-citationVaduganathan, M., Mentz, R. J., Claggett, B. L., Miao, Z. M., Kulac, I. J., Ward, J. H., Hernandez, A. F., Morrow, D. A., Starling, R. C., Velazquez, E. J., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad344 · Cited by 142
“PARAGON-HF also suggested clinical benefits in a broader population of patients with chronic HF, but did not meet statistical significance.(2) As such, there might be residual uncertainties about clinical benefit when interpreting either trial in isolation.”
BackgroundSelf-citationIdentification of distinct phenotypic clusters in heart failure with preserved ejection fraction
Uijl, A., Savarese, G., Vaartjes, I. C. H., Dahlström, U., Brugts, J. J., Linssen, G. C. M., van Empel, V. P. M., Rocca, H. B., Asselbergs, F. W., Lund, L. H., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2169 · Cited by 143
Neprilysin Inhibitors in Heart Failure
Bozkurt, B., Nair, A. P., Misra, A., Scott, C. Z., Mahar, J. H., & Fedson, S. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2022.05.010 · Cited by 161
“Subgroup analysis showed benefit with sacubitril-valsartan among those with an ejection fraction (EF) in the lower range (EF: <57%) and women.(60)”
BackgroundFrisk, M., Le, C., Shen, X. M., Røe, Å. T., Hou, Y., Manfra, O., da Silva, G. J. J., van Hout, I., Nordén, E. S., Aronsen, J. M., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.044 · Cited by 138
Filippatos, G., Butler, J., Farmakis, D., Zannad, F., Ofstad, A. P., Ferreira, J. P., Green, J. B., Rosenstock, J., Schnaidt, S., Brueckmann, M., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059785 · Cited by 131
Self-citationLópes, R. D., Alexander, K. P., Stevens, S. R., Reynolds, H. R., Stone, G. W., Piña, I. L., Rockhold, F. W., Elghamaz, A., Lopez-Sendon, J. L., Farsky, P. S., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.050304 · Cited by 140
Self-citationCurrent and future therapeutic perspective in chronic heart failure
Mascolo, A., di Mauro, G., Cappetta, D., Angelis, A. D., Torella, D., Urbanek, K., Berrino, L., Nicoletti, G. F., Capuano, A., & Rossi, F. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106035 · Cited by 150
Diabetic cardiomyopathy: Clinical phenotype and practice
Zhao, X., Liu, S., Wang, X., Chen, Y., Pang, P., Yang, Q., Lin, J., Deng, S., Shen-tao, W., Fan, G., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1032268 · Cited by 135
“However, in patients with HFpEF (EF ≥45%), sacubitril/valsartan did not significantly reduce heart failure hospital izations or cardiovascular mortal i ty (228).”
BackgroundDevice-based therapies for arterial hypertension
Lauder, L., Azizi, M., Kirtane, A. J., Böhm, M., & Mahfoud, F. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0364-1 · Cited by 132
Peikert, A., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Litwin, S. E., Zile, M. R., Desai, A. S., Jhund, P. S., Butt, J. H., Lam, C. S. P., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf057 · Cited by 132
Self-citationPandey, A. K., Bhatt, D. L., Pandey, A. K., Marx, N., Cosentino, F., Pandey, A., & Verma, S. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad389 · Cited by 143
Sex and gender differences in myocarditis and dilated cardiomyopathy: An update
Fairweather, D., Beetler, D. J., Musigk, N., Heidecker, B., Lyle, M. A., Cooper, L. T., & Bruno, K. A. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1129348 · Cited by 124
Heart–brain interactions in cardiac and brain diseases: why sex matters
Rossi, A., Mikaïl, N., Bengs, S., Haider, A., Treyer, V., Buechel, R. R., Wegener, S., Rauen, K., Tawakol, A. A., Merz, C. N. B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac061 · Cited by 130
O’Meara, E., McDonald, M., Chan, M., Ducharme, A., Ezekowitz, J. A., Giannetti, N., Grzeslo, A., Heckman, G. A., Howlett, J. G., Koshman, S. L., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.11.036 · Cited by 122
Proteomic Signatures of Heart Failure in Relation to Left Ventricular Ejection Fraction
Adamo, L., Yu, J., Resende, C. R., Javaheri, A., Head, R. D., & Mann, D. L. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.061 · Cited by 125
“Indeed, the recent results of the PARAGON (A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients [NYHA Class II-IV] With Preserved Ejection Fraction) trial (19), wherein…”
Edema formation in congestive heart failure and the underlying mechanisms
Abassi, Z. A., Khoury, E. E., Karram, T., & Aronson, D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.933215 · Cited by 145
“Indeed, studies have shown that dual blockade of AT1R and NEP in HF patients was more efficient in reducing the mortality from cardiovascular causes or hospitalization due to worsening HF than was ACE inhibition alone (159, 160).”
BackgroundThe win ratio in cardiology trials: lessons learnt, new developments, and wise future use
Pocock, S., Gregson, J., Collier, T. J., Ferreira, J. P., & Stone, G. W. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae647 · Cited by 132
“In HF trials, there is interest in incorporating repeat hospitalizations into analysis either as a primary composite endpoint, e.g. PARAGON-HF 18 or COAPT, 12 or as a key secondary endpoint, e.g. EMPEROR 6,19 or DELIVER.”
Cunningham, J. W., Vaduganathan, M., Claggett, B. L., Zile, M. R., Anand, I. S., Packer, M., Zannad, F. M., Lam, C. S. P., Janssens, S. P., Jhund, P. S., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.03.002 · Cited by 123
Self-citationvon Haehling, S., Arzt, M. E., Doehner, W., Edelmann, F., Evertz, R., Ebner, N., Herrmann‐Lingen, C., Garfias‐Veitl, T., Koziolek, M. J., Noutsias, M., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1838 · Cited by 126
Chronic low‐grade inflammation in heart failure with preserved ejection fraction
Mesquita, T., Lin, Y., & Ibrahim, A. G.-E. (2021) · Aging Cell · doi:10.1111/acel.13453 · Cited by 130
Detecting structural heart disease from electrocardiograms using AI
Poterucha, T. J., Jing, L., Ricart, R. P., Adjei-Mosi, M., Finer, J., Hartzel, D., Kelsey, C., Long, A., Rocha, D., Ruhl, J. A., et al. (2025) · Nature · doi:10.1038/s41586-025-09227-0 · Cited by 116
Cunningham, J. W., Claggett, B. L., O’Meara, E., PRESCOTT, M. F., Pfeffer, M. A., Shah, S. J., Redfield, M. M., Zannad, F. M., Chiang, L., Rizkala, A. R., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.072 · Cited by 115
Self-citation2024 EACTS Guidelines on perioperative medication in adult cardiac surgery
Jeppsson, A., (Sweden), (.-C., Rocca, B., (Italy), (.-C., Hansson, E. C., (Sweden), Guðbjartsson, T., (Iceland), James, S. K., (Sweden), et al. (2024) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezae355 · Cited by 131
Ejection fraction and mortality: a nationwide register‐based cohort study of 499 153 women and men
Stewart, S., Playford, D. A., Scalia, G. M., Currie, P. J., Celermajer, D. S., Prior, D., Codde, J., Strange, G. A., & on behalf of the NEDA Investigators (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2047 · Cited by 119
Jering, K., Claggett, B. L., Pfeffer, M. A., Granger, C. B., Køber, L., Lewis, E. F., Maggioni, A. P., Mann, D. L., McMurray, J. J. V., Rouleau, J. L., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2191 · Cited by 123
Self-citation2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D. A., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A. M., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.02.009 · Cited by 118
Law, J. P., Pickup, L. C., Pavlović, D., Townend, J., & Ferro, C. J. (2022) · Journal of Human Hypertension · doi:10.1038/s41371-022-00751-4 · Cited by 136
“PARAGON-HF studied 4,796 patients with LV ejection fraction ≥45% and reported no significant change in heart failure hospitalisations and cardiovascular death when compared to valsartan alone [242].”
Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
Ceriello, A., Catrinoiu, D., Chandramouli, C., Cosentino, F., Dombrowsky, A. C., Itzhak, B., Lalic, N. M., Prattichizzo, F., Schnell, O., Seferovic, P. M., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01408-1 · Cited by 126
“As mentioned earlier, HF is mainly categorized in HFrEF, HFpEF, and HFmrEF on the basis of LVEF.”
BackgroundResultInfluentialRelationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction
Salah, H. M., Pandey, A., Soloveva, A. E., Abdelmalek, M. F., Diehl, A. M., Moylan, C. A., Wegermann, K., Rao, V. N., Hernandez, A. F., Tedford, R. J., et al. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.07.010 · Cited by 119
“In the light of recent evidence suggesting possible benefits of the combination of the neprilysin inhibitor prodrug sacubitril and the angiotensin receptor blocker valsartan in patients with HFpEF and lownormal ejection fraction and possible improvement in patients reported outcomes (111,112), the Food and Drug Admini…”
BackgroundSGLT2-inhibitors; more than just glycosuria and diuresis
Fathi, A., Vickneson, K., & Singh, J. S. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10038-w · Cited by 109
“The lack of efficacy seen with ACE-inhibitors/ARBs [37–39], MRAs [40] and sacubitril / valsartan [41] in HFpEF suggest that excessive loading is not a key pathogenic mechanism or adverse adaptation in this HF phenotype.”
Background2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 167
Self-citationLong-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis
Yafasova, A., Fosbøl, E. L., Schou, M., Gustafsson, F., Rossing, K., Bundgaard, H., Lauridsen, M. D., Kristensen, S. L., Torp-Pedersen, C., Gislason, G. H., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.06.038 · Cited by 104
Abraham, W. T., Psotka, M. A., Fiuzat, M., Filippatos, G. S., Lindenfeld, J. M., Mehran, R., Ambardekar, A. V., Carson, P. E., Jacob, R., Januzzi, J. L., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.10.002 · Cited by 123
Self-citationSignaling cascades in the failing heart and emerging therapeutic strategies
He, X., Du, T., Long, T., Liao, X., Dong, Y., & Huang, Z. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00972-6 · Cited by 114
Cunningham, J. W., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Desai, A. S., Jhund, P. S., de Boer, R. A., DeMets, D. L., Hernandez, A. F., Inzucchi, S. E., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.07.021 · Cited by 108
Self-citationTargeting Cyclic Guanosine Monophosphate to Treat Heart Failure
Emdin, M., Aimo, A., Castiglione, V., Vergaro, G., Georgiopoulos, G. A., Saccaro, L. F., Lombardi, C., Passino, C., Cerbai, E., Metra, M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.031 · Cited by 112
Self-citationTherapeutic approaches in heart failure with preserved ejection fraction: past, present, and future
Wintrich, J., Kindermann, I., Ukena, C., Selejan, S., Werner, C. M., Maack, C., Laufs, U., Tschöpe, C., Anker, S. D., Lam, C. S. P., et al. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01633-w · Cited by 113
Self-citationIncidence and Outcomes of Pneumonia in Patients With Heart Failure
Shen, L., Jhund, P. S., Anand, I. S., Bhatt, A. S., Desai, A. S., Maggioni, A. P., Martínez, F. A., Pfeffer, M. A., Rizkala, A. R., Rouleau, J. L., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.03.001 · Cited by 113
Self-citationMarin‐Neto, J. A., Rassi, A., de Oliveira, G. M. M., Correia, L. C. L., Ramos, A. N., Luquetti, A. O., Hasslocher‐Moreno, A. M., de Sousa, A. S., de Paola, Â. A. V., Sousa, A. C. S., et al. (2023) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20230269 · Cited by 166
von Haehling, S., Doehner, W., Evertz, R., Garfias‐Veitl, T., Derad, C., Diek, M., Karakas, M., Birkemeyer, R., Fillippatos, G., Lainščak, M., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae479 · Cited by 111
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., Cherney, D. Z. I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155931 · Cited by 103
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98
“Likewise, sacubitril–valsartan did not significantly improve the rate of total HF hospitalizations and CV death in HFpEF patients with respect to valsartan alone [161].”
BackgroundAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
van de Bovenkamp, A. A., van Rossum, A. C., & Handoko, M. L. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2000284 · Cited by 98
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Christensen, L., Davies, M., Hovingh, K. G., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · JACC: Heart Failure · doi:10.1016/j.jchf.2023.05.010 · Cited by 97
Self-citationCardiovascular Disease Screening in Women: Leveraging Artificial Intelligence and Digital Tools
Adedinsewo, D. A., Pollak, A. W., Phillips, S. D., Smith, T. L., Svatikova, A., Hayes, S. N., Mulvagh, S. L., Norris, C., Roger, V. L., Noseworthy, P. A., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.319876 · Cited by 85
Cyclic GMP and PKG Signaling in Heart Failure
Numata, G., & Takimoto, E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.792798 · Cited by 105
“As previously described, ARNI exhibited favorable outcome in female patients with HFpEF (Solomon et al., 2019; Pieske et al., 2021).”
ResultHeart failure with preserved ejection fraction: insights into diagnosis and pathophysiology
Nagueh, S. F. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa228 · Cited by 88
Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases
Yang, F., Xue, J., Wang, G., & Diao, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.999404 · Cited by 118
Kapelios, C. J., Shahim, B., Lund, L. H., & Savarese, G. (2023) · Cardiac failure review · doi:10.15420/cfr.2023.03 · Cited by 105
Heart Failure with Preserved Ejection Fraction
Cannata, A. N., & McDonagh, T. A. (2025) · New England Journal of Medicine · doi:10.1056/nejmcp2305181 · Cited by 109
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction
Butt, J. H., Dewan, P., Jhund, P. S., Anand, I. S., Atar, D., Ge, J., Desai, A. S., Echeverría, L. E., Køber, L., Lam, C. S. P., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.06.037 · Cited by 100
“01), however.(21) In this post hoc analysis, we examined the efficacy and safety of sacubitril/valsartan according to frailty status, using the Rockwood cumulative deficit approach.”
MethodSelf-citationButler, J., Abildstrøm, S. Z., Borlaug, B. A., Davies, M. J., Kitzman, D. W., Petrie, M. C., Shah, S. J., Verma, S., Abhayaratna, W. P., Chopra, V., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.09.811 · Cited by 88
Self-citationRole of Cardiac Natriuretic Peptides in Heart Structure and Function
Sarzani, R., Allevi, M., Pentima, C. D., Schiavi, P., Spannella, F., & Giulietti, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214415 · Cited by 102
Dewan, P., Jackson, A. M., Lam, C. S. P., Pfeffer, M. A., Zannad, F. M., Pitt, B., Solomon, S. D., & McMurray, J. J. V. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1776 · Cited by 94
Self-citationThe Impact of Patients With Cardiac Amyloidosis in HFpEF Trials
Oghina, S., Bougouin, W., Bézard, M., Kharoubi, M., Komajda, M., Solal, A. C., Mebazaa, A., Damy, T., & Bodez, D. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2020.12.005 · Cited by 99
Mancia, G., Kjeldsen, S. E., Kreutz, R., Pathak, A., Grassi, G., & Esler, M. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19020 · Cited by 85
Medical Therapies for Heart Failure With Preserved Ejection Fraction
Kjeldsen, S. E., von Lueder, T. G., Smiseth, O. A., Wachtell, K., Mistry, N., Westheim, A. S., Hopper, I., Julius, S., Pitt, B., Reid, C. M., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.14057 · Cited by 98
Self-citationZhazykbayeva, S., Pabel, S., Mügge, A., Sossalla, S. T., & Hamdani, N. (2020) · Biophysical Reviews · doi:10.1007/s12551-020-00742-0 · Cited by 97
“Some trials such as the recent PARAGON-HF trial that investigated the effects of sacubitril/valsartan in patients with HFrEF showed evidence of a very heterogeneous response to treatment (Solomon et al. 2019).”
BackgroundOraii, A., McIntyre, W. F., Parkash, R., Kowalik, K., Razeghi, G., Benz, A. P., Belley‐Côté, E. P., Conen, D., Connolly, S. J., TANG, A. S. L., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.0675 · Cited by 103
Sex difference in human diseases: mechanistic insights and clinical implications
Shi, Y., Ma, J., Li, S., Liu, C., Liu, Y., Chen, J., Liu, N., Liu, S., & Huang, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01929-7 · Cited by 94
“114 As for β receptor blockers, carvedilol has more bene fi ts in treating male heart failure, while metoprolol improves heart failure better in women.”
Ohya, Y., Arakawa, K., Arata, N., Arima, S., Arima, H., Asayama, K., Dohi, Y., Fukami, A., Furuhashi, M., Goto, K., et al. (2026) · Hypertension Research · doi:10.1038/s41440-025-02462-y · Cited by 107
Selvaraj, S., Claggett, B. L., Böhm, M., Anker, S. D., Vaduganathan, M., Zannad, F., Pieske, B., Lam, C. S. P., Anand, I. S., Shi, V. C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.009 · Cited by 86
“The Prospective Comparison of ARNI [angiotensin receptor–neprilysin inhibitor] with ARB [angiotensin-receptor blockers] Global Outcomes in HF with Preserved Ejection Fraction (PARAGON-HF) trial is the largest randomized study in HFpEF to date (12), and whether the anti-hypertensive effects of sacubitril/valsartan medi…”
BackgroundSelf-citationLejeune, S., Roy, C., Ciocea, V., Slimani, A., de Meester, C., Amzulescu, M. S., Pasquet, A., Vancraeynest, D., Beauloye, C., Vanoverschelde, J., et al. (2020) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2020.02.016 · Cited by 91
Abudureyimu, M., Luo, X., Wang, X., Sowers, J. R., Wang, W., Ge, J., Ren, J. T., & Zhang, Y. (2022) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjac028 · Cited by 96
Self-citationNatriuretic peptide pathways in heart failure: further therapeutic possibilities
Sangaralingham, S. J., Kühn, M., Cannone, V., Chen, H. H., & Burnett, J. C. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac125 · Cited by 88
Kosiborod, M. N., Bhatt, A. S., Claggett, B. L., Vaduganathan, M., Kulac, I. J., Lam, C. S. P., Hernandez, A. F., Martinez, F. A., Inzucchi, S. E., Shah, S. J., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.006 · Cited by 86
Self-citationFinerenone and Kidney Outcomes in Patients With Heart Failure
Mc Causland, F. R., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Desai, A. S., Jhund, P. S., Henderson, A. D., Brinker, M., Perkins, R., Scheerer, M. F., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.10.091 · Cited by 86
Self-citationPagel, P. S., Tawil, J. N., Boettcher, B. T., Izquierdo, D. A., Lazicki, T. J., Crystal, G. J., & Freed, J. K. (2020) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2020.07.016 · Cited by 98
Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials
Fiuzat, M., HAMO, C. E., Butler, J., Abraham, W. T., DeFilippis, E. M., Fonarow, G. C., Lindenfeld, J. M., Mentz, R. J., Psotka, M. A., Solomon, S. D., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.033 · Cited by 89
Self-citationMongirdienė, A., Skrodenis, L., Varoneckaitė, L., Mierkytė, G., & Gerulis, J. (2022) · Biomedicines · doi:10.3390/biomedicines10030602 · Cited by 90
Contemporary pharmacological treatment and management of heart failure
Bozkurt, B. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-00997-0 · Cited by 96
Fitchett, D., Inzucchi, S. E., Zinman, B., Wanner, C., Schumacher, M., Schmoor, C., Ohneberg, K., Ofstad, A. P., Salsali, A., George, J. T., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13615 · Cited by 85
Self-citationVardeny, O., Fang, J. C.-T., Desai, A. S., Jhund, P. S., Claggett, B. L., Vaduganathan, M., de Boer, R. A., Hernandez, A. F., Lam, C. S. P., Inzucchi, S. E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02102-9 · Cited by 85
Self-citationPugliese, N. R., Biase, N. D., Conte, L., Gargani, L., Mazzola, M., Fabiani, I., Natali, A., Dini, F. L., Frumento, P., Rosada, J., et al. (2020) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2020.08.015 · Cited by 89
Heart Failure in the Last Year: Progress and Perspective
Tomasoni, D., Adamo, M., Anker, M. S., von Haehling, S., Coats, A. J. S., & Metra, M. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13124 · Cited by 102
Pugliese, N. R., Biase, N. D., Gargani, L., Mazzola, M., Conte, L., Fabiani, I., Natali, A., Dini, F. L., Frumento, P., Rosada, J., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa129 · Cited by 89
Primary and Secondary Outcome Reporting in Randomized Trials
Pocock, S. J., Rossello, X., Owen, R., Collier, T. J., Stone, G. W., & Rockhold, F. W. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.024 · Cited by 78
Kaur, G., & Lau, E. S. (2022) · Women s Health · doi:10.1177/17455057221140209 · Cited by 113
Obokata, M., Sorimachi, H., Harada, T., Kagami, K., Saito, Y., & Ishii, H. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.09.018 · Cited by 83
How to Manage Heart Failure With Preserved Ejection Fraction
Desai, A. S., Lam, C. S. P., McMurray, J. J. V., & Redfield, M. M. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.03.011 · Cited by 97
Self-citationSpannella, F., Giulietti, F., Filipponi, A., & Sarzani, R. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13002 · Cited by 90
Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction
Jackson, A. M., Rørth, R., Liu, J., Kristensen, S. L., Anand, I. S., Claggett, B. L., Cleland, J. G. F., Chopra, V. K., Desai, A. S., Ge, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2403 · Cited by 80
Self-citationKasiakogias, A., Rosei, E. A., Camafort, M., Ehret, G., Faconti, L., Ferreira, J. P., Brguljan-Hitij, J., Januszewicz, A., Kahan, T., Manolis, A. J., et al. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002910 · Cited by 87
“001), with the treatment effect extending across the spectrum of baseline renal function, has been demonstrated [69,98].”
BackgroundResultInfluentialSelf-citationHeart failure with preserved ejection fraction based on aging and comorbidities
Lin, Y. H., Fu, S., Yao, Y., Li, Y., Zhao, Y., & Luo, L. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02935-x · Cited by 85
Inflammatory Mechanisms in Heart Failure with Preserved Ejection Fraction
Daou, D., Gillette, T. G., & Hill, J. A. (2023) · Physiology · doi:10.1152/physiol.00004.2023 · Cited by 95
2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure
Kittleson, M. M., Benjamin, E. J., Blumer, V., Harrington, J., Januzzi, J. L., McMurray, J. J. V., & Vest, A. R. (2025) · JACC · doi:10.1016/j.jacc.2025.05.008 · Cited by 79
Self-citationHypertension: Current trends and future perspectives
Hunter, P. G., Chapman, F. A., & Dhaun, N. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14825 · Cited by 94
“Additionally, there were more adverse events, including hypotension and angioedema, with Entresto.(85)”
BackgroundInfluential
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., Redfield, M. M., Rouleau, J. L., van Veldhuisen, D. J., Zannad, F., Zile, M. R., Desai, A. S., Claggett, B., Jhund, P. S., Boytsov, S. A., Comin-Colet, J., Cleland, J., Düngen, H.-D., Goncalvesova, E., Katova, T., Kerr Saraiva, J. F., Lelonek, M., Merkely, B., Senni, M., Shah, S. J., Zhou, J., Rizkala, A. R., Gong, J., Shi, V. C., & Lefkowitz, M. P.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (S.D.S., M.A.P., A.S.D., B.C.); the British Heart Foundation Cardiovascular Research Centre (J.J.V.M., P.S.J.) and the Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Well-being (J.C.), University of Glasgow, Glasgow, and the National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London (J.C.) — all in the United Kingdom; University of...
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Anand, Inder S.
- Ge, Junbo
- Lam, Carolyn S.P.
- Maggioni, Aldo P.
- Packer, Milton
- Pfeffer, Marc A.
- Pieske, Burkert
- Redfield, Margaret M.
- Rouleau, Jean L.
- Zannad, Faiez
- Zile, Michael R.
- Desai, Akshay S.
- Claggett, Brian
- Jhund, Pardeep S.
- Boytsov, Sergey A.
- Cleland, John
- Düngen, Hans-Dirk
- Lelonek, Małgorzata
- Senni, Michele
- Shah, Sanjiv J.
- Zhou, Jingmin
- Rizkala, Adel R.
- Gong, Jianjian
- Shi, Victor C.
- Lefkowitz, Martin P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-24
- Volume
- 381
- Issue
- 17
- Pages
- 1609-1620
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2971294569
- Cited by
- 2,430
- References
- 25
- Citations by year
- 2026: 258 · 2025: 296 · 2024: 338 · 2023: 361 · 2022: 414 · 2021: 385 · 2020: 318 · 2019: 55
- FWCI
- 211.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Research Bank (Australian Catholic University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- sacubitril/valsartan, valsartan, angiotensin receptor-neprilysin inhibition, heart failure with preserved ejection fraction, heart failure hospitalization, cardiovascular mortality, NYHA functional class, renal function, Kansas City Cardiomyopathy Questionnaire, natriuretic peptides, structural heart disease, drug safety, adverse events, anemia of chronic kidney disease, hyperkalemia
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angioedema, Biphenyl Compounds, Cardiovascular Diseases, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Hypotension, Male, Middle Aged, Quality of Life, Sex Factors, Stroke Volume, Tetrazoles, Neprilysin, Single-Blind Method, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.